The latest announcement is out from Innate Pharma SA ( (FR:IPH) ).
Innate Pharma announced its participation in the 2025 Stifel Virtual Targeted Oncology Forum, scheduled for April 8-9, 2025, where its executive team will present and host one-on-one meetings. This engagement reflects Innate Pharma’s strategic efforts to strengthen its industry presence and foster collaborations, potentially impacting its operations and stakeholder relationships positively.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes its proprietary ANKET® platform for NK Cell Engagers, as well as Antibody Drug Conjugates and monoclonal antibodies, to address various tumor types. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.
Technical Sentiment Signal: Sell
Current Market Cap: $168.7M
For an in-depth examination of IPH stock, go to TipRanks’ Stock Analysis page.